|
Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. It is currently being investigated as a treatment for relapsed or refractory peripheral T-cell lymphoma. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Alisertib」の詳細全文を読む スポンサード リンク
|